Evaluating 3 months of treatment for patient with atopic dermatitis. Treatments will be either monthly injections of Lebrikizumab or treatment with topical corticosteroids alone.
SPONSOR: F.HOFFMAN LA ROCHE LTD.
Protocol Title: AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
For patients with mild to moderate psoriasis looking at different dosages and application frequency for a topical treatment. This involves 12 weeks of treatment with study treatment or placebo. Approximately 9 visits over a 5 month duration.
SPONSOR: GLAXOSMITHKLEIN GROUP OF COMPANIES
Protocol title: Study 203120: A Randomized, Blinded, Vehicle-Controlled,Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Evaluating the effectiveness and safety of treatment with Humira or CHS-1420. Patients will received an injection every other week for 24 weeks and come into the office for approximately 12 visits over an 8 month duration.
SPONSOR: COHERUS BIOSCIENCES INC.
Protocol Title: A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira® in Subjects With Chronic Plaque Psoriasis
For patients with acne on face and trunk, 12 weeks of daily topical treatment to evaluate the safety and effectiveness of the study treatment or placebo. This study has approximately 7 visits over a 4 month duration.
SPONSOR: GALDERMA R&D
Protocol Title: A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
Contact us today if you’re interested in learning more about these studies or our clinical trials department: email@example.com.